https://survivinpathway.com/yo....ur-bioavailability-r
Risk factors for fragility fractures, assessment strategies, ideal time when it comes to treatment, dosing/duration of treatment, and post therapy monitoring have not been plainly defined in HR + early breast and NMPC patients receiving endocrine treatment. This review is designed to talk about the utility of break danger assessment (FRAX) tool for the prevention and handling of CTIBL, osteoanabolic treatment for imminent break danger decrease, and sequential therapy opti
Like
Comment
Share
